INmune Bio Inc. (INMB)
NASDAQ: INMB · Real-Time Price · USD
1.400
-0.070 (-4.76%)
At close: Apr 28, 2026, 4:00 PM EDT
1.450
+0.050 (3.57%)
After-hours: Apr 28, 2026, 5:04 PM EDT
INmune Bio Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for INmune Bio stock have an average target of 5.40, with a low estimate of 0.60 and a high estimate of 9.00. The average target predicts an increase of 285.71% from the current stock price of 1.40.
Analyst Consensus: Buy
* Price targets were last updated on Mar 11, 2026.
Analyst Ratings
The average analyst rating for INmune Bio stock from 5 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 5 | 5 | 5 | 5 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LUCID CAPITAL MARKETS | LUCID CAPITAL MARKETS | Hold → Strong Buy Upgrades $2 → $9 | Hold → Strong Buy | Upgrades | $2 → $9 | +542.86% | Mar 11, 2026 |
| Freedom Broker | Freedom Broker | Strong Buy Maintains $7 → $4 | Strong Buy | Maintains | $7 → $4 | +185.71% | Aug 12, 2025 |
| Freedom Broker | Freedom Broker | Strong Buy Initiates $7 | Strong Buy | Initiates | $7 | +400.00% | Jul 3, 2025 |
| Maxim Group | Maxim Group | Strong Buy Maintains $30 → $8 | Strong Buy | Maintains | $30 → $8 | +471.43% | Jul 2, 2025 |
| BTIG | BTIG | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jul 1, 2025 |
Financial Forecast
Revenue This Year
n/a
from 50.00K
Revenue Next Year
6.49M
EPS This Year
-0.87
from -1.86
EPS Next Year
-0.90
from -0.87
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 15.9M | ||||||
| Avg | n/a | 6.5M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.71 | -0.54 | ||||||
| Avg | -0.87 | -0.90 | ||||||
| Low | -1.03 | -1.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.